Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study
- Details
- Category: Bayer
Bayer HealthCare, in partnership with its development partner Janssen Research & Development, LLC, announced a collaboration with the Population Health Research Institute (PHRI) and the Canadian Stroke Prevention Intervention Network (C-SPIN) to conduct the global Phase III NAVIGATE ESUS study.
Pfizer to Acquire Hospira
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world's leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion.
AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
- Details
- Category: AstraZeneca
AstraZeneca and Actavis Plc today announced that they have entered into a definitive agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold.
Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award
- Details
- Category: GlaxoSmithKline
A simple mobile-phone app that helps staff at human milk banks (HMBs) with the pasteurisation of donor breast milk and a life-saving kit for the treatment of diarrhoea in under-fives have been awarded joint first prize in the annual GSK and Save the Children $1 million Healthcare Innovation Award.
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
- Details
- Category: AstraZeneca
AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company's key therapeutic areas.
Bristol-Myers Squibb reports fourth quarter and full year 2014 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company's immuno-oncology (I-O) portfolio.
Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial
- Details
- Category: GlaxoSmithKline
GSK has announced that the first batch of its candidate Ebola vaccine is being shipped to west Africa and is expected to arrive in Liberia later today Friday 23 January. The shipment, containing an initial 300 vials of the candidate vaccine, is the first to arrive in one of the main Ebola affected countries and will be used to start the first large-scale efficacy trial of experimental Ebola vaccines in the coming weeks.
More Pharma News ...
- Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need
- Novartis Pharmaceuticals announces a joint investment company with Qualcomm
- Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
- MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
- Acquisition provides Pfizer with a preclinical CMV vaccine candidate
- Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
- Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) sign worldwide research collaboration